Compare · CV vs MDT
CV vs MDT
Side-by-side comparison of CapsoVision Inc. (CV) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CV and MDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $106.51B, about 328.5x CV ($324.3M).
- Over the past year, CV is up 51.8% and MDT is down 9.6% - CV leads by 61.4 points.
- MDT has been more active in the news (4 items in the past 4 weeks vs 3 for CV).
- MDT has more recent analyst coverage (25 ratings vs 2 for CV).
- Company
- CapsoVision Inc.
- Medtronic plc.
- Price
- $6.55-0.46%
- $83.19+1.43%
- Market cap
- $324.3M
- $106.51B
- 1M return
- -7.88%
- +3.82%
- 1Y return
- +51.80%
- -9.57%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 3
- 4
- Recent ratings
- 2
- 25
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest CV
- Large owner Harari Eliyahou Et Al bought $410,988 worth of shares (61,068 units at $6.73) (SEC Form 4)
- Large owner Harari Eliyahou Et Al bought $495,117 worth of shares (81,300 units at $6.09) (SEC Form 4)
- Large owner Harari Eliyahou Et Al bought $101,811 worth of shares (13,850 units at $7.35) (SEC Form 4)
- SEC Form 4 filed by Director Shields David Stanley
- New insider Shields David Stanley claimed no ownership of stock in the company (SEC Form 3)
- CapsoVision Inc. filed SEC Form 8-K: Regulation FD Disclosure
- CapsoVision Appoints Gastroenterology Leader David S. Shields, M.D., to Board of Directors
- Director Imperial Joanne Carol exercised 2,022 shares at a strike of $7.58, increasing direct ownership by 120% to 3,709 units (SEC Form 4)
- Amendment: Director Imperial Joanne Carol sold $8,587 worth of shares (1,200 units at $7.16), decreasing direct ownership by 42% to 1,687 units (SEC Form 4)
- Director Tsai Chen Lung exercised 2,022 shares at a strike of $7.58, increasing direct ownership by 70% to 4,929 units (SEC Form 4)
Latest MDT
- A new era for surgery with real-time AI: Medtronic to unveil Touch Surgery™ Aide, the next-generation compute platform for the operating room at Society of Robotic Surgery 2026
- Medtronic to announce financial results for its first quarter of fiscal year 2027
- Medtronic completes acquisition of SPR, expanding patient access to minimally invasive, non-opioid treatment of chronic and acute pain
- SVP, Chief HR Officer Walter Matthew R. sold $257,931 worth of Ordinary Shares (3,102 units at $83.15), decreasing direct ownership by 8% to 35,694 units (SEC Form 4)
- New insider Thompson Kweli claimed ownership of 30,018 units of Ordinary Shares (SEC Form 3)
- SEC Form IRANNOTICE filed by Medtronic plc.
- SEC Form 10-K filed by Medtronic plc.
- Medtronic completes acquisition of Scientia Vascular, seamlessly integrating access and therapeutic portfolios for neurovascular care
- EVP & President Cardiovascular Kiil Harry Skip sold $336,965 worth of Ordinary Shares (4,189 units at $80.44), decreasing direct ownership by 10% to 37,227 units (SEC Form 4)
- EVP & President Cardiovascular Kiil Harry Skip covered exercise/tax liability with 6,817 units of Ordinary Shares, decreasing direct ownership by 14% to 41,416 units (SEC Form 4)